CD4 and neoplasm: Notably, the combination of ONCOS-204 and EGFRxCD3 BsAb exhibits superior ability in augmenting T cell activation and cytotoxicity compared to ONCOS-102, with ONCOS-204 particularly significantly influencing CD4+ T cell subpopulations infected with tumor cells (44).